Caplacizumab
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Caplacizumab |
| DrugBank ID | DB06081 |
| Brand Names (EU) | Cablivi |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 100.00% |
Approved Indication (EMA)
Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | primary release disorder of platelets | 100.00% | DL |
| 2 | pseudo-von Willebrand disease | 100.00% | DL |
| 3 | Glanzmann thrombasthenia | 100.00% | DL |
| 4 | Scott syndrome | 100.00% | DL |
| 5 | thrombotic thrombocytopenic purpura | 100.00% | DL |
| 6 | bleeding diathesis due to a collagen receptor defect | 100.00% | DL |
| 7 | hemorrhagic disorder due to a constitutional thrombocytopenia | 100.00% | DL |
| 8 | fetal and neonatal alloimmune thrombocytopenia | 99.99% | DL |
| 9 | hemophilia | 99.99% | DL |
| 10 | platelet-type bleeding disorder | 99.99% | DL |
| 11 | acquired coagulation factor deficiency | 99.99% | DL |
| 12 | thrombocytopenic purpura | 99.98% | DL |
| 13 | Ehlers-Danlos syndrome, fibronectinemic type | 99.98% | DL |
| 14 | inherited thrombophilia | 99.97% | DL |
| 15 | flood factor deficiency | 99.97% | DL |
| 16 | symptomatic form of hemophilia in female carriers | 99.97% | DL |
| 17 | congenital factor V deficiency | 99.97% | DL |
| 18 | hereditary thrombocytosis with transverse limb defect | 99.96% | DL |
| 19 | familial thrombomodulin anomalies | 99.96% | DL |
| 20 | methylcobalamin deficiency type cblG | 99.96% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.